Greenwich LifeSciences
GLSI
27 hedge funds and large institutions have $5.64M invested in Greenwich LifeSciences in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
19% more capital invested
Capital invested by funds: $4.75M → $5.64M (+$888K)
13% more funds holding
Funds holding: 24 → 27 (+3)
0.01% less ownership
Funds ownership: 4.18% → 4.17% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$210K |
| 2 |
6CM
683 Capital Management
New York
|
+$197K |
| 3 |
Jane Street
New York
|
+$140K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$134K |
| 5 |
Citigroup
New York
|
+$95.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$405K |
| 2 |
Renaissance Technologies
New York
|
-$177K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$97.8K |
| 4 |
Squarepoint
New York
|
-$97K |
| 5 |
Millennium Management
New York
|
-$76.6K |
GLSI Hedge Fund Activity: Q4 2023 in Review
27 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q4 2023, worth a combined $5.64M — up 19% from $4.75M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GLSI positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $210K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $405K sold.
- 27 institutional investors held Greenwich LifeSciences (GLSI) as of Q4 2023, up from 24 in Q3 2023.
- Funds reported $5.64M of Greenwich LifeSciences stock for Q4 2023, up 19% quarter-over-quarter.
- 6 funds opened new Greenwich LifeSciences positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest Greenwich LifeSciences buyer in Q4 2023 was Northern Trust, an estimated $210K added.
- The largest Greenwich LifeSciences seller in Q4 2023 was GSA Capital Partners, an estimated $405K sold.
Based on aggregated 13F filings for Q4 2023.